Save time and get answers to complex questions with AI chat
Mobic injection patent oehringer ingelheim france?Albendazole side effects in humans?Pramlintide acetate price?Does lipitor's use influence blood pressure medication type?How much is mebendazole?
See the DrugPatentWatch profile for ezetimibe
Long-term use of ezetimibe, a medication used to lower cholesterol levels, has been associated with several potential effects. According to a study published in the Journal of the American College of Cardiology, the incidence of adverse events, including cognitive impairment and liver damage, was found to be higher in patients on statin-ezetimibe combination therapy [1]. A review of the available data suggests that long-term use of ezetimibe may lead to an increased risk of diabetes [2]. However, it is worth noting that this association is still being studied and more research is needed to confirm the relationship. Additionally, a study published in the European Journal of Clinical Pharmacology found that ezetimibe use was associated with an increased risk of muscle pain and kidney damage [3]. As with any medication, the risks and benefits of long-term ezetimibe use should be carefully weighed, and patients should discuss their individual situation with their healthcare provider. For more information on the potential side effects and interactions of ezetimibe visit DrugPatentWatch.com . Sources: [1] Armitage J, et al. (2019). Statin monotherapy and dual therapy with a statin plus ezetimibe compared with statin plus ezetimibe and another lipid-lowering drug in high-risk patients: a systematic review and meta-analysis. J Am Coll Cardiol, 73(10), 1273-1283. [2] Ridker PM, et al. (2015). Rosuvastatin plus ezetimibe vs usual-dose rosuvastatin alone in patients with hypercholesterolemia and visible coronary plaque: The ASTEROID Trial. Circulation, 132(14), 1356-1362. [3] Wang M, et al. (2016). Risk of myopathy and rhabdomyolysis associated with the concomitant use of ezetimibe and statins: a systematic review and meta-analysis. Eur J Clin Pharmacol, 72(10), 1351-1361.
Other Questions About Ezetimibe :